Company
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 9 of 16
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medi
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
"I am particularly pleased to confirm funds released through the hedging facility will not carry any geographical restrictions. This means we will be able to deploy capital across our entire portfolio," said CEO, Matt Lofgran
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Petro Matad was the morning's standout loser, with its shares losing more than 35%, meanwhile, in the blue-chip market the supermarkets were moving higher.
The AIM-listed biotechnology company said the funds raised will be used for “advancing the clinical dose escalation of VAL201 and for further progressing the late pre-clinical development of GeneICE and general working capital purposes”
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The biotech has made a few tweaks to its VAL101 molecule which is now showing “much improved technical efficacy and commercially viable efficient manufacturing”
A glance at some of the bigger risers and fallers today in London ...
Mystic Pharmaceuticals will get access to ValiRx's patented technology, including pre-clinical products
Despite the beating meted out to IMPs and BATs, the Footsie rallied in the last half hour to trim its heavy losses
Archive
A glance at some of the stories on the Proactive newswire today
A look at the biggest risers and fallers in London today
Seppo Mäkinen, Dr Ajay Agrawal and Andrew King bring with them a wealth of industry and commercial experience
The FTSE 100 dropped 8.5 to close at 7,439 on the day
Archive
A glance at some of the small cap stories on Proactive Investors today
Risers and fallers: DFS, Next, ANGLE boosted by Barts research, Starcom wins container order, Sprue Aegis delivers bullish AGM
